XtalPi launches Kodexia, an AI-driven platform for siRNA medicines, with six programmes advancing

What's the deal? On 6 October 2026, XtalPi debuted Kodexia, which it calls the industry's first closed-loop platform for discovering small interfering RNA (siRNA) drugs. siRNAs are a class of medicine that silence disease-causing genes inside cells by intercepting their messenger RNA, stopping the production of harmful proteins. Kodexia combines generative AI with physics-based biological modelling and automated lab experiments, so each round of computer-designed molecules is rapidly synthesised and tested, with the results fed back into the models to improve the next design.

Validating the platform: Alongside the launch, XtalPi said six proprietary siRNA programmes are advancing across metabolic, kidney, respiratory and central nervous system diseases, with the first programme reaching non-human primate data in seven months. The company reports a roughly threefold improvement in molecular-design efficiency versus conventional workflows, and a first-round in-vivo hit rate above 50% across multiple target programmes. Kodexia's delivery technology is also designed to take RNA therapies beyond the liver, which has historically been the main destination of approved siRNA drugs.

Why it matters: XtalPi, founded by MIT-trained physicists and listed in Hong Kong (HKEX: 2228), has built its reputation pairing AI with robotics for small-molecule discovery. Kodexia extends that engine into nucleic-acid therapeutics — the modality behind blockbusters such as Alnylam's cholesterol drug inclisiran — positioning XtalPi to compete in the fast-growing siRNA market both through its own pipeline and through partnerships with drug developers.

Read more: PR Newswire, 6 Oct 2026